Bisphosphonates for the treatment of osteoporosis: Insights for clinicians

Therapeutic Advances in Chronic Disease

Volumn 1, Issue 3, 2010, Pages 115-128

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

benefit; bisphosphonate; efficacy; osteoporosis; risk; safety; treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GENERIC DRUG; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ARTHRALGIA; ARTICLE; ATYPICAL SUBTROCHANTERIC FEMUR FRACTURE; BONE MINERAL; BONE PAIN; BONE TURNOVER; CONTINUOUS INFUSION; DIGESTIVE SYSTEM INJURY; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; ELDERLY CARE; ESOPHAGUS CANCER; FATIGUE; FEMUR FRACTURE; FLU LIKE SYNDROME; FRACTURE HEALING; FRACTURE NONUNION; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; MALABSORPTION; MYALGIA; NAUSEA; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION;

EID: 79952929410     PISSN: 20406223     EISSN: None     Source Type: Journal    
DOI: 10.1177/2040622310374783     Document Type: Review

References (109)

1. Abrahamsen, B., Eiken, P. and Eastell, R. (2009) More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360: 1789-1792.
2. Adachi, J.D., Adami, S., Miller, P.D., Olszynski, W.P., Kendler, D.L., Silverman, S.L. et al. (2001) Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 13: 347-354.
3. Adachi, J.D., Faraawi, R.Y., O'Mahony, M.F., Nayar, A., Massaad, R., Evans, J.K. et al. (2009) Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study. Clin Ther 31: 1747-1753.
4. Aguirre, L.E. and Lewiecki, E.M. (2009) Management of osteoporosis in elderly women. Ann Long-Term Care: Clin Care Aging 17 (10): 35-39.
5. Armamento-Villareal, R., Napoli, N., Panwar, V. and Novack, D. ( 2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355: 2048-2050.
6. Baim, S., Binkley, N., Bilezikian, J.P., Kendler, D.L., Hans, D.B., Lewiecki, E.M. et al. (2008) Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCDPosition Development Conference. J Clin Densitom 11: 75-91.
7. Black, D.M., Cummings, S.R., Karpf, D.B., Cauley, J.A., Thompson, D.E., Nevitt, M.C. et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541.
8. Black, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A. et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809-1822.
9. Black, D.M., Kelly, M.P., Genant, H.K., Palermo, L., Eastell, R., Bucci-Rechtweg, C. et al. (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362: 1761-1771.
10. Black, D.M., Schwartz, A.V., Ensrud, K.E., Cauley, J.A., Levis, S., Quandt, S.A. et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927-2938.
11. Black, D.M., Thompson, D.E., Bauer, D.C., Ensrud, K., Musliner, T., Hochberg, M.C. et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 85: 4118-4124.
12. Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P. et al. (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199.
13. Boonen, S., McClung, M.R., Eastell, R., El-Hajj, F.G., Barton, I.P. and Delmas, P. ( 2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52: 1832-1839.
14. Brown, J.P., Kendler, D.L., McClung, M.R., Emkey, R.D., Adachi, J.D., Bolognese, M.A. et al. (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tiss Int 71: 103-111.
15. Caro, J.J., Ishak, K.J., Huybrechts, K.F., Raggio, G. and Naujoks, C. ( 2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15: 1003-1008.
16. Center, J.R., Nguyen, T.V., Schneider, D., Sambrook, P.N. and Eisman, J.A. ( 1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353: 878-882.
17. Chesnut III, C.H., McClung, M.R., Ensrud, K.E., Bell, N.H., Genant, H.K., Harris, S.T. et al. (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99: 144-152.
18. Chesnut III, C.H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J.A., Hoiseth, A. et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241-1249.
19. Clowes, J.A., Peel, N.F. and Eastell, R. ( 2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89: 1117-1123.
20. Cooper, A., Drake, J. and Brankin, E. ( 2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60: 896-905.
21. Cooper, C. ( 1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103(2A): 12S-19S.
22. Cooper, C., Campion, G. and Melton III, L.J. ( 1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2: 285-289.
23. Cramer, J.A., Gold, D.T., Silverman, S.L. and Lewiecki, E.M. ( 2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18: 1023-1031.
24. Cryer, B. and Bauer, D.C. ( 2002) Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77: 1031-1043.
25. Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A. et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial. JAMA 280: 2077-2082.
26. Cummings, S.R., Schwartz, A.V. and Black, D.M. ( 2007) Alendronate and atrial fibrillation. N Engl J Med 356: 1895-1896.
27. Delmas, P.D., Adami, S., Strugala, C., Stakkestad, J.A., Reginster, J.Y., Felsenberg, D. et al. (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54: 1838-1846.
28. Delmas, P.D., Benhamou, C.L., Man, Z., Tlustochowicz, W., Matzkin, E., Eusebio, R. et al. (2008 a) Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 19: 1039-1045.
29. Delmas, P.D., McClung, M.R., Zanchetta, J.R., Racewicz, A., Roux, C., Benhamou, C.L. et al. (2008 b) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42: 36-42.
30. Dunford, J.E., Thompson, K., Coxon, F.P., Luckman, S.P., Hahn, F.M., Poulter, C.D. et al. (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Therapeutics 296: 235-242.
31. Epstein, S., Cryer, B., Ragi, S., Zanchetta, J.R., Walliser, J., Chow, J. et al. (2003) Disintegration / dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 19: 781-789.
32. Ettinger, M.P., Felsenberg, D., Harris, S.T., Wasnich, R., Skag, A., Hiltbrunner, V. et al. (2005) Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol 32: 1968-1974.
33. European Foundation for Osteoporosis and Bone Disease, National Osteoporosis Foundation (1997) Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7: 1-6.
34. Fleisch, H.( 2000) Bisphosphonates in Bone Disease: From the Laboratory to the Patient, 4th edn, Academic Press: San Diego, CA.
35. Fleisch, H. ( 2001) Can bisphosphonates be given to patients with fractures ? J Bone Miner Res 16: 437-440.
36. Fujiwara, S., Nakamura, T., Orimo, H., Hosoi, T., Gorai, I., Oden, A. et al. (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19: 429-435.
37. Goh, S.K., Yang, K.Y., Koh, J.S., Wong, M.K., Chua, S.Y., Chua, D.T. et al. (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89: 349-353.
38. Goldhahn, J., Little, D., Mitchell, P., Fazzalari, N.L., Reid, I.R., Aspenberg, P. et al. (2010) Evidence for anti-osteoporosis therapy in acute fracture situations-recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone 46: 267-271.
39. Hamilton, B., McCoy, K. and Taggart, H. ( 2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14: 259-262.
40. Harrington, J.T., Barash, H.L., Day, S. and Lease, J. ( 2005) Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 53: 198-204.
41. Harris, S.T., Blumentals, W.A. and Miller, P.D. ( 2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24: 237-245.
42. Harris, S.T., Watts, N.B., Genant, H.K., McKeever, C.D., Hangartner, T., Keller, M. et al. (1999 a) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344-1352.
43. Harris, S.T., Watts, N.B., Genant, H.K., McKeever, C.D., Hangartner, T., Keller, M. et al. (1999 b) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis-a randomized controlled trial. JAMA 282: 1344-1352.
44. Heckbert, S.R., Li, G., Cummings, S.R., Smith, N.L. and Psaty, B.M. ( 2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168: 826-831.
45. Hewitt, R.E., Lissina, A., Green, A.E., Slay, E.S., Price, D.A. and Sewell, A.K. ( 2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139: 101-11.
46. Hochberg, M.C., Thompson, D.E., Black, D.M., Quandt, S.A., Cauley, J., Geusens, P. et al. (2005) Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 20: 971-976.
47. Jamal, S.A., Bauer, D.C., Ensrud, K.E., Cauley, J.A., Hochberg, M., Ishani, A. et al. (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22 (4): 503-8.
48. Kanis, J.A., Burlet, N., Cooper, C., Delmas, P.D., Reginster, J.Y., Borgstrom, F. et al. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19: 399-428.
49. Kanis, J.A. on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report, World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield: Sheffield, UK.
50. Khosla, S., Burr, D., Cauley, J., Dempster, D.W., Ebeling, P.R., Felsenberg, D. et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res 22: 1479-1489.
51. Kimmel, D.B., Recker, R.R., Gallagher, J.C., Vaswani, A.S. and Aloia, J.F. ( 1990) A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects. Bone Miner 11: 217-235.
52. Klibanski, A., Adams-Campbell, L., Bassford, T., Blair, S.N., Boden, S.D., Dickersin, K. et al. (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785-795.
53. Lee, P., van der Wall, H. and Seibel, M.J. ( 2007) Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 30: 590-597.
54. Lenart, B.A., Neviaser, A.S., Lyman, S., Chang, C.C., Edobor-Osula, F., Steele, B. et al. (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20: 1353-1362.
55. Lewiecki, E.M. ( 2003) Nonresponders to osteoporosis therapy. J Clin Densitom 6: 307-314.
56. Lewiecki, E.M. (2009) Managing osteoporosis: challenges and strategies. Cleve Clin J Med 76: 457-466.
57. Lewiecki, E.M. and Binkley, N. (2009) Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. Endocr Pract 24: 1643-1646.
58. Lewiecki, E.M., Cooper, C., Thompson, E., Hartl, F., Mehta, D. and Papapoulos, S.E. ( 2010) Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract. [Epub ahead of print].
59. Lewiecki, E.M. and Miller, P.D. ( 2007) Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 6: 663-672.
60. Lewiecki, E.M. and Watts, N.B. ( 2008) Assessing response to osteoporosis therapy. Osteoporos Int 19: 1363-1368.
61. Lyles, K.W., Colon-Emeric, C.S., Magaziner, J.S., Adachi, J.D., Pieper, C.F., Mautalen, C. et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799-1809.
62. Maalouf, N.M., Heller, H.J., Odvina, C.V., Kim, P.J. and Sakhaee, K. ( 2006) Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 12: 48-53.
63. MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M. et al. (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148: 197-213.
64. Marx, R.E. ( 2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117.
65. Marx, R.E., Sawatari, Y., Fortin, M. and Broumand, V. ( 2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575.
66. McClung, M.R., Geusens, P., Miller, P.D., Zippel, H., Bensen, W.G., Roux, C. et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333-340.
67. McCombs, J.S., Thiebaud, P., Laughlin-Miley, C. and Shi, J. ( 2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48: 271-287.
68. Mellstrom, D.D., Sorensen, O.H., Goemaere, S., Roux, C., Johnson, T.D. and Chines, A.A. ( 2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 462-468.
69. Miller, P.D. ( 2005) Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 3: 5-12.
70. Miller, P.D., McClung, M.R., Macovei, L., Stakkestad, J.A., Luckey, M., Bonvoisin, B. et al. (2005 a) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20: 1315-1322.
71. Miller, P.D., Roux, C., Boonen, S., Barton, I.P., Dunlap, L.E. and Burgio, D.E. ( 2005b) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20: 2105-2115.
72. Miller, P.D., Woodson, G., Licata, A.A., Ettinger, M.P., Mako, B., Smith, M.E. et al. (2000) Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Therapeutics 22: 1433-1442.
73. Nancollas, G.H., Tang, R., Phipps, R.J., Henneman, Z., Gulde, S., Wu, W. et al. (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617-627.
74. National Osteoporosis Foundation (2008) Clinician's Guide to Prevention and Treatment of Osteoporosis, National Osteoporosis Foundation: Washington, DC.
75. Neviaser, A.S., Lane, J.M., Lenart, B.A., Edobor-Osula, F. and Lorich, D.G. ( 2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22: 346-350.
76. Odvina, C.V., Zerwekh, J.E., Rao, D.S., Maalouf, N., Gottschalk, F.A. and Pak, C.Y. ( 2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294-1301.
77. Perazella, M.A. and Markowitz, G.S. ( 2008) Bisphosphonate nephrotoxicity. Kidney Int 74: 1385-1393.
78. Perkins, A.C., Blackshaw, P.E., Hay, P.D., Lawes, S.C., Atherton, C.T., Dansereau, R.J. et al. (2008) Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther 30: 834-844.
79. Peter, C.P., Handt, L.K. and Smith, S.M. ( 1998) Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 43: 1998-2002.
80. Pols, H.A.P., Felsenberg, D., Hanley, D.A., Stepan, J., Munoz-Torres, M., Wilkin, T.J. et al. (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 9: 461-468.
81. Recker, R.R., Lewiecki, E.M., Miller, P.D. and Reiffel, J. ( 2009) Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 122(2 Suppl): S22-S32.
82. Reginster, J.-Y., Minne, H.W., Sorensen, O.H., Hooper, M., Roux, C., Brandi, M.L. et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11: 83-91.
83. Reid, I.R., Brown, J.P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U. et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653-661.
84. Ringe, J.D. and Moller, G. ( 2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int. [Epub ahead of print].
85. Rizzoli, R., Bruyere, O., Cannata-Andia, J.B., Devogelaer, J.P., Lyritis, G., Ringe, J.D. et al. (2009) Management of osteoporosis in the elderly. Curr Med Res Opin 25: 2373-2387.
86. Rosen, C.J., Hochberg, M.C., Bonnick, S.L., McClung, M., Miller, P., Broy, S. et al. (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20: 141-151.
87. Russell, R.G., Bisaz, S., Fleisch, H., Currey, H.L., Rubinstein, H.M., Dietz, A.A. et al. (1970) Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet 2: 899-902.
88. Russell, R.G., Watts, N.B., Ebetino, F.H. and Rogers, M.J. ( 2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19: 733-759.
89. Schneider, J.P. ( 2006) Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 61: 31-33.
90. Schnitzer, T.J., Bone, H.G., Crepaldi, G., Adami, S., McClung, M., Pinchera, A. et al. (2000) Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily for treatment of postmenopausal osteoporosis. Aging Clin Exp Res 12: 1-12.
91. Schwartz, A.V., Bauer, D.C., Cummings, S.R., Cauley, J.A., Ensrud, K.E., Palermo, L. et al. (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX trial. J Bone Miner Res 25: 976-982.
92. Sebba, A. ( 2008) Osteoporosis: how long should we treat? Curr Opin Endocrinol Diabetes Obes 15: 502-507.
93. Shakweh, M., Bravo-Osuna, I. and Ponchel, G. ( 2007) Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. Eur J Pharm Sci 31: 262-270.
94. Siminoski, K., Leslie, W.D., Frame, H., Hodsman, A., Josse, R.G., Khan, A. et al. (2007) Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 10: 120-123.
95. Simon, J.A., Lewiecki, E.M., Smith, M.E., Petruschke, R.A., Wang, L. and Palmisano, J.J. ( 2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24: 1871-1886.
96. Solomon, D.H., Patrick, A. and Brookhart, M.A. (2009) More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360: 1789-1790.
97. Sorensen, H.T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R.D., Cummings, S.R. et al. (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336: 813-816.
98. US Food and Drug Administration (2008 a) Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm (accessed 23 March 2010).
99. US Food and Drug Administration (2008 b) Update of Safety Review Follow-up to the October 1, 2007. Early Communication about the Ongoing Safety Review of Bisphosphonates. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm (accessed 24 March 2010).
100. US Food and Drug Administration (2010) FDA Drug Safety Communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm (accessed 23 March 2010).
101. Watts, N.B., Chines, A., Olszynski, W.P., McKeever, C.D., McClung, M.R., Zhou, X. et al. (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19: 365-372.
102. Wilkes, M.M., Navickis, R.J., Chan, W.W. and Lewiecki, E.M. (2010) Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant / persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int 21: 679-688.
103. Woo, C., Gao, G., Wade, S. and Hochberg, M.C. ( 2010) Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin 26: 1003-1009.
104. Woo, S.B., Hellstein, J.W. and Kalmar, J.R. ( 2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761.
105. World Health Organization (1994) Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis, WHO: Geneva, Switzerland.
106. World Health Organization (2009) FRAX WHO Fracture Risk Assessment Tool. Available at http://www.shef.ac.uk/FRAX/ (accessed 11 November 2009).
107. Wysowski, D.K. ( 2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360: 89-90.
108. Wysowski, D.K. and Chang, J.T. ( 2005) Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 165: 346-347.
109. Yood, R.A., Emani, S., Reed, J.I., Lewis, B.E., Charpentier, M. and Lydick, E. ( 2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14: 965-968.